Drug Resistance in Colorectal Cancer: From Mechanism to Clinic.
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic.
复制标题
结直肠癌的耐药性：从机制到临床
作者：
Chemotherapy, radiotherapy and molecularly targeted therapy could improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy, especially immune checkpoint inhibitors, has significantly improved the prognosis of some patients. However, drug resistance significantly reduces the usefulness of these drugs. Although research on the molecular mechanisms underlying the emergence of drug resistance is ongoing, the specific molecular mechanisms remain unclear. This article reviews the findings on the mechanisms of drug resistance in CRC patients in preclinical and clinical studies, which may provide valuable directions for future in-depth study of drug resistance. Colorectal cancer (CRC) is one of the leading causes of death worldwide. The 5-year survival rate is 90% for patients with early CRC, 70% for patients with locally advanced CRC, and 15% for patients with metastatic CRC (mCRC). In fact, most CRC patients are at an advanced stage at the time of diagnosis. Although chemotherapy, molecularly targeted therapy and immunotherapy have significantly improved patient survival, some patients are initially insensitive to these drugs or initially sensitive but quickly become insensitive, and the emergence of such primary and secondary drug resistance is a significant clinical challenge. The most direct cause of resistance is the aberrant anti-tumor drug metabolism, transportation or target. With more in-depth research, it is found that cell death pathways, carcinogenic signals, compensation feedback loop signal pathways and tumor immune microenvironment also play essential roles in the drug resistance mechanism. Here, we assess the current major mechanisms of CRC resistance and describe potential therapeutic interventions.
登录
查看更多内容
影响因子：
28.2
作者：
Bardelli A;Corso S;Bertotti A;Hobor S;Valtorta E;Siravegna G;Sartore-Bianchi A;Scala E;Cassingena A;Zecchin D;Apicella M;Migliardi G;Galimi F;Lauricella C;Zanon C;Perera T;Veronese S;Corti G;Amatu A;Gambacorta M;Diaz LA Jr;Sausen M;Velculescu VE;Comoglio P;Trusolino L;Di Nicolantonio F;Giordano S;Siena S
通讯作者：
Siena S
DOI：
10.1186/2008-2231-22-47
发表时间：
2014-06-05
期刊：
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
影响因子：
--
作者：
Akbari A;Amanpour S;Muhammadnejad S;Ghahremani MH;Ghaffari SH;Dehpour AR;Mobini GR;Shidfar F;Abastabar M;Khoshzaban A;Faghihloo E;Karimi A;Heidari M
通讯作者：
Heidari M
影响因子：
3.6
作者：
Bachman, KE;Argani, P;Park, BH
通讯作者：
Park, BH
影响因子：
16.6
作者：
Bronte V;Brandau S;Chen SH;Colombo MP;Frey AB;Greten TF;Mandruzzato S;Murray PJ;Ochoa A;Ostrand-Rosenberg S;Rodriguez PC;Sica A;Umansky V;Vonderheide RH;Gabrilovich DI
通讯作者：
Gabrilovich DI
DOI：
10.1016/j.ejca.2015.04.007
发表时间：
2015-07
期刊：
European journal of cancer (Oxford, England : 1990)
影响因子：
--
作者：
Bokemeyer C;Köhne CH;Ciardiello F;Lenz HJ;Heinemann V;Klinkhardt U;Beier F;Duecker K;van Krieken JH;Tejpar S
通讯作者：
Tejpar S